Acceleron Pharma Inc. (XLRN) Rises to $48.60 on Jun, 29

June 29, 2018 - By Darrin Badillo

Acceleron Pharma Inc. (NASDAQ:XLRN) Corporate Logo

During Q1 2018 the big money sentiment increased to 1.27. That’s change of 0.18, from 2017Q4’s 1.09. 13 investors sold all, 39 reduced holdings as Acceleron Pharma Inc. ratio increased. 42 increased stakes while 24 funds bought stakes. Funds hold 38.30 million shares thus 0.44% more from 2017Q4’s 38.14 million shares.
Principal Fincl Group Inc invested in 0.01% or 135,491 shs. 1.07M are held by Polar Llp. Teacher Retirement System Of Texas has 0% invested in Acceleron Pharma Inc. (NASDAQ:XLRN). Aqr Management Limited Liability Com holds 0% or 9,537 shs. Meeder Asset Management Inc holds 0% or 127 shs. Royal Bancorporation Of Canada holds 32 shs. Pictet Asset Mgmt Limited accumulated 516,073 shs. 86,811 are owned by Tiaa Cref Mngmt Ltd Com. 28,300 were accumulated by Waddell Reed Financial Incorporated. Amer Int Grp Incorporated accumulated 23,997 shs. Franklin Resource Inc owns 435,577 shs for 0.01% of their capital. Congress Asset Mngmt Ma holds 0.01% of its capital in Acceleron Pharma Inc. (NASDAQ:XLRN) for 15,488 shs. Deutsche Fincl Bank Ag has invested 0.01% in Acceleron Pharma Inc. (NASDAQ:XLRN). 307,330 are held by Dekabank Deutsche Girozentrale. Ubs Asset Mngmt Americas Inc reported 412,310 shs.

Acceleron Pharma Inc. had 12 insider sales and 0 insider buys since January 2, 2018. This’s net activity of $4.08 million. The insider MCLAUGHLIN KEVIN F sold 4,000 shs worth $153,792. POPS RICHARD F sold $1.55 million worth of Acceleron Pharma Inc. (NASDAQ:XLRN) on Tuesday, March 6. On Friday, January 12 Rovaldi Christopher had sold 11,000 shs worth $495,000. On Tuesday, April 3 4,600 shs were sold by Sherman Matthew L, worth $176,772. $183,806 worth of Acceleron Pharma Inc. (NASDAQ:XLRN) shs were sold by Quisel John D.

Acceleron Pharma Inc. (NASDAQ:XLRN) increased significantly to $48.60. On Jun, 29 the move was announced by Barchart.com. It has $2.23 billion MC. The company’s valuation will be $66.75M more at $50.06 target.

Acceleron Pharma Inc. (NASDAQ:XLRN)’s earnings report is anticipated on August, 2., as reported by Faxor. This year’s earnings per share analyst estimate is anticipated to be $-0.64. That is 16.88 % up compareed to $-0.77 earnings per share for last year. Wall Street now forecasts 10.34 % negative EPS growth despite Acceleron Pharma Inc. previous quarter’s EPS of $-0.58.

Acceleron Pharma Inc. (NASDAQ:XLRN) Ratings Coverage

A total of 7 analysts rate Acceleron Pharma (NASDAQ:XLRN) as follows: 5 “Buy”, 2 “Hold” and 0 “Sell”. Тherefore 71% are bullish. (NASDAQ:XLRN) has 9 ratings reports on Jun 29, 2018 according to StockzIntelligence. On Wednesday, February 28 Barclays Capital maintained Acceleron Pharma Inc. (NASDAQ:XLRN) rating. Barclays Capital has “Overweight” rating and $54 target. In Wednesday, February 28 report H.C. Wainwright maintained it with “Buy” rating and $62.0 target. On Tuesday, May 22 the firm earned “Hold” rating by Oppenheimer. On Friday, June 29 the firm has “Outperform” rating by Credit Suisse given. On Friday, June 29 Goldman Sachs upgraded Acceleron Pharma Inc. (NASDAQ:XLRN) rating. Goldman Sachs has “Neutral” rating and $40 target. On Thursday, March 1 Citigroup maintained the shares of XLRN in report with “Buy” rating. On Monday, February 26 JP Morgan upgraded Acceleron Pharma Inc. (NASDAQ:XLRN) to “Overweight” rating. On Monday, January 8 the stock of Acceleron Pharma Inc. (NASDAQ:XLRN) has “Buy” rating given by H.C. Wainwright. On Wednesday, March 28 the company was initiated by H.C. Wainwright.

For more Acceleron Pharma Inc. (NASDAQ:XLRN) news released briefly go to: Benzinga.com, Benzinga.com, 247Wallst.com, Benzinga.com or Businesswire.com. The titles are as follows: “Benzinga’s Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos” released on June 29, 2018, “Mid-Day Market Update: Crude Oil Up Over 1%; Gemphire Therapeutics Shares Spike Higher” on June 29, 2018, “Top Analyst Upgrades and Downgrades: Accenture, Ally, Diageo, Harley-Davidson, KB Home, NetApp, Nike, Sirius XM …” with a publish date: June 29, 2018, “Benzinga’s Top Upgrades, Downgrades For June 29, 2018” and the last “Acceleron to Present Preliminary Data on ACE-083 at the 2018 Annual Meeting of the Peripheral Nerve Society” with publication date: June 26, 2018.

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for serious and rare diseases.The firm is worth $2.23 billion. The Company’s therapeutic candidates include luspatercept to treat anemia and associated complications in patients with myelodysplastic syndromes and beta-thalassemia; and sotatercept for chronic kidney diseases.Last it reported negative earnings. The companyÂ’s therapeutic candidates also include dalantercept, a tyrosine kinase inhibitor, which is in phase II clinical trials for renal cell carcinoma; and ACE-083 that is in phase II clinical trials for facioscapulohumeral dystrophy.

Acceleron Pharma Inc. (NASDAQ:XLRN) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: